Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Eisai Medical Research Inc. |
---|---|
Information provided by: | Eisai Medical Research Inc. |
ClinicalTrials.gov Identifier: | NCT00539929 |
This is a double-blind, multicenter study to assess the efficacy and safety of E6201 topical administration to pre-identified marker lesions in adult subjects with chronic plaque type psoriasis. Treatment duration is 8 weeks, followed by a 4-week period without treatment. PK samples will be obtained pre-and post treatment.
Condition | Intervention | Phase |
---|---|---|
Chronic Plaque Psoriasis |
Drug: E6201 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Proof of Principle, Randomized, Parallel-Group, Double-Blind, Vehicle-Controlled, Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis |
Estimated Enrollment: | 100 |
Study Start Date: | September 2007 |
Estimated Study Completion Date: | October 2008 |
Estimated Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator |
Drug: E6201
Cream, twice daily.
|
2: Placebo Comparator |
Drug: E6201
Cream, twice daily.
|
3: Placebo Comparator |
Drug: E6201
Cream, twice daily.
|
4: Placebo Comparator |
Drug: E6201
Cream, once daily.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
EXCLUSION CRITERIA
United States, Texas | |
Dr. Terry Jones, M.D. | |
Bryan, Texas, United States, 77802 |
Study Director: | Michael Kuligowski, MD | Eisai Medical Research Inc. |
Responsible Party: | Eisai Medical Research Inc. ( Ger Rikken, M.D., Study Director ) |
Study ID Numbers: | E6201-A001-201 |
Study First Received: | October 3, 2007 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00539929 |
Health Authority: | United States: Food and Drug Administration |
Skin Diseases Psoriasis Skin Diseases, Papulosquamous |